About us

YUMAB is a biotechnology company founded in 2012 by experts and pioneers in recombinant antibody technologies of the University of Braunschweig, Germany. Since then, YUMAB has become a world leading provider for the development of fully human, therapeutic antibodies. YUMAB offers outstanding expertise from more than 30 years of continuous research in recombinant antibody technologies in combination with state of the art and next generation technologies. This unique setting enables novel solutions for current and future challenges in antibody immunotherapy.

Our capabilities:

1. Fast track discovery of fully human or humanized antibodies

2. YUMAB antibody library technologies: human, patient, different animal species incl. immunization of llama/alpaca (VHH), rabbit, mouse, chicken, also transgenic animals, ...) - NEW! H+L paired libraries

3. Technology platforms for all modalities: IgG, Fab, scFv, bispecifics, CAR, ADC, AOCs

4. Antibody engineering (affinity, stability, manufacturability) 

5. AI enabled in silico lead optimization combined with experimental studies

6. Antibody sequencing and (super-)humanization

7. Tool development for preclinical and clinical assays

8. Target discovery & validation 

9. Contract and partnered research and development (FTE based research)